A randomized, double-blind, placebo-controlled study of intrathecal baclofen for cerebral palsy

Lire cet article en français


  • Intrathecal baclofen (ITB) treatment of cerebral palsy (CP) for 3-months resulted in significantly more achievement of individual treatment goals than placebo.

Why this matters

  • This study provides level 2 evidence that ITB may be a treatment option for those with severe dyskinetic CP with poor response to oral therapies.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.